Citigroup Inc 89bio, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 418,259 shares of ETNB stock, worth $3.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

418,259

Previous 214,602 94.9%

Holding current value

$3.18 Million

Previous $2.4 Million 103.09%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.13 - $13.77 $1.66 Million - $2.8 Million	203,657 Added 94.9%	418,259 $4.87 Million
Q4 2023 Feb 09, 2024	BUY	$6.66 - $16.03 $351,288 - $845,518	52,746 Added 32.59%	214,602 $2.4 Million
Q3 2023 Nov 09, 2023	BUY	$15.06 - $19.41 $411,047 - $529,776	27,294 Added 20.28%	161,856 $2.5 Million
Q2 2023 Aug 10, 2023	SELL	$14.15 - $22.03 $3.52 Million - $5.49 Million	-249,026 Reduced 64.92%	134,562 $2.55 Million
Q1 2023 May 11, 2023	SELL	$10.48 - $16.94 $1.63 Million - $2.63 Million	-155,091 Reduced 28.79%	383,588 $5.84 Million

Q4 2022 Feb 09, 2023	BUY	$7.81 - $12.73 $999,929 - $1.63 Million	128,032 Added 31.18%	538,679 $6.86 Million
Q3 2022 Nov 10, 2022	BUY	$3.02 - $7.0 $561,780 - $1.3 Million	186,020 Added 82.81%	410,647 $2.38 Million
Q2 2022 Aug 10, 2022	BUY	$2.09 - $4.02 $467,666 - $899,531	223,764 Added 25928.62%	224,627 $723,000
Q1 2022 May 12, 2022	SELL	$3.45 - $14.99 $7,876 - $34,222	-2,283 Reduced 72.57%	863 $3,000
Q4 2021 Feb 10, 2022	BUY	$11.15 - $19.66 $22,221 - $39,182	1,993 Added 172.85%	3,146 $41,000
Q3 2021 Nov 10, 2021	BUY	$14.91 - $21.31 $17,191 - $24,570	1,153 New	1,153 $23,000

Others Institutions Holding ETNB

# of Institutions

164

Shares Held

89.1M

Call Options Held

584K

Put Options Held

1.17M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $353M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account